Regeneron's Extended Eylea Dosing Plan Suffers US FDA Delay
Executive Summary
Competitors are moving forward on wet AMD products with longer dosing intervals, with Novartis close to filing with FDA.
You may also be interested in...
Allergan's Abicipar Effective With Fewer Injections, But More Inflammation In AMD
Allergan and Molecular Partners said dosing of the VEGF inhibitor every eight or 12 weeks was non-inferior to Lucentis every four weeks. But while AMD patients would enjoy fewer sharp pokes in the eye, about 15% may experience inflammation – at least until a new formulation is available.
Novartis Pharma CEO Paul Hudson Discusses Leadership And Launches
Hudson has gained his footing running Novartis' pharma business. Now, he's preparing to launch seven new drugs by 2020 while growing Cosentyx, Entresto and other in-line products.
Novartis Back In AMD Game With ‘Potential Blockbuster’ Brolucizumab
Novartis says nAMD eye treatment brolucizumab showed further advantages over Eylea in two Phase III studies, reinforcing plans to file in late 2018 for a commercial launch in 2019.